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ABBREVIATIONS 37 
ART: Arterial revascularization trial  38 
BITA: Bilateral internal thoracic arteries 39 
BMI: Body mass index  40 
CABG: coronary artery bypass grafting  41 
CVA: cerebrovascular accident  42 
COPD: chronic obstructive pulmonary disease 43 
ITA: internal thoracic artery  44 
LVEF: left ventricular ejection fraction  45 
MACCE: major cardiac and cerebrovascular events 46 
MI: myocardial infarction 47 
PCI: percutaneous coronary intervention  48 
POAF: postoperative atrial fibrillation  49 
PS: propensity score 50 
SITA: Single internal thoracic artery  51 
SVG: saphenous vein grafts  52 
SMD: standardized mean difference   53 
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Central Message: The incidence of intraoperative bilateral internal thoracic artery (BITA) 54 
graft conversion in the ART was not irrelevant despite participating surgeons were requested 55 
to have expertise in BITA grafts.  56 
 57 
Prospective statement: Reasons beyond bilateral internal thoracic artery (BITA) grafts 58 
underutilization remain unclear. In the ART participating surgeons were requested to have 59 
expertise in BITA grafts. We found that in the ART the incidence of intraoperative BITA 60 
graft conversion was not irrelevant thus supporting that BITA grafts may represent a 61 
challenge also for experienced surgeons.  62 
  63 
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Abstract 64 
Background: The arterial revascularization trial (ART) has been designed to answer the 65 
question whether the use of bilateral internal thoracic arteries (BITA) can improve 10-year 66 
outcomes when compared to single internal thoracic artery (SITA). In the ART, a significant 67 
proportion of patients initially allocated to BITA received other conduit strategies. We sought 68 
to investigate the incidence and clinical implication of BITA grafts conversion in the ART. 69 
Methods: Among patients enrolled in the ART (n=3102), we excluded those allocated to 70 
SITA (n=1554), those who did not undergo surgery (n=16) and those operated on but 71 
withdrew after randomization (n=7). Propensity score matching was used to compare 72 
converted vs non-converted BITA groups. 73 
Results: A total of 1525 patients were operated with intention to receive BITA grafting. Of 74 
those, 233 (15.3%) were converted to other conduit selection strategies. Incidence of 75 
conversion largely varied across 28 centres involved (from 0% to 42.9%). The most common 76 
reason for BITA grafts conversion was the evidence of at least one internal thoracic artery not 77 
suitable which was reported in 77 cases. Patients with intraoperative BITA graft conversion 78 
received a lower number of grafts (2.95±0.84 vs 3.21±0.74; P<0.001). However, hospital 79 
mortality rate was comparable to those who did not require BITA graft conversion (0 vs 80 
1.6%; P=0.1) as well as the incidence of major complications. At 5 years we found a non-81 
significant excess of deaths (11.9% vs 8.4%; P=0.1) and major adverse events (17.1% 13.2%; 82 
P=0.1) mainly driven by an excess of revascularization in patients requiring conversion.  83 
Conclusions: The incidence of intraoperative BITA graft conversion is not irrelevant . BITA 84 
graft conversion is not associated with increased operative morbidity but its effect on late 85 
outcomes remain uncertain.   86 
Keywords: bilateral internal thoracic artery; randomised controlled trial; outcomes 87 
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Despite evidence from large observational studies have consistently suggested that the use of 88 
bilateral internal thoracic artery (BITA) graft improves long term survival when compared to 89 
single internal thoracic artery (SITA) graft in coronary artery bypass graft (CABG) surgery 90 
[1,2], the use of BITA graft remains particularly low. As a matter of fact, BITA grafting 91 
represents only 4–12% of all CABG procedures over the more traditional use of the SITA 92 
with additional saphenous vein grafts (SVG) [3]. Reasons for BITA underutilization are 93 
multifactorial. Most of surgeons just do not perform BITA grafting based on the increased 94 
risk of sternal wound complications and technical complexity [4,5]. However, same patients 95 
initially intended to receive BITA grafts requires intraoperative conversion to other conduits 96 
strategies. Incidence and causes of intraoperative BITA grafts conversion and its clinical 97 
implication has never been investigated.  98 
The arterial revascularization trial (ART) has been designed to answer the question whether 99 
the use of bilateral internal thoracic arteries (BITA) can improve 10-year outcomes when 100 
compared to single internal thoracic artery (SITA) in coronary artery bypass grafting (CABG) 101 
[6]. Interim 5-year results have shown similar clinical outcomes between the two groups [7]. 102 
In ART only surgeons with experience of ≥50 BITA operations were able to undertake BITA 103 
procedures in the trial [6]. We sought to investigate reasons for intraoperative BITA grafts 104 
conversion and its clinical implication by performing a post-hoc analysis of the ART.    105 
Methods  106 
A post-hoc analysis of 5-year outcomes of the ART trial was conducted. This research 107 
adheres to the principles set forth in the Declaration of Helsinki 108 
(http://www.wma.net/en/30publications/10policies/b3/index.html). Among patients enrolled 109 
in the ART (n=3102) from 2004 to 2007, we excluded those allocated to SITA (n=1554) and 110 
those who did not undergo surgery (n=16) and those operated on but withdrew after 111 
randomization (n=7).  112 
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Trial design 113 
The ART was approved by the institutional review board of all participating centers, and 114 
informed consent was obtained from each participant. The protocol for the ART has been 115 
published [6]. Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 116 
hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. 117 
Eligible patients were those with multivessel coronary artery disease undergoing CABG. 118 
BITA grafts configuration (y graft vs. in-situ graft vs. free graft) was left at discretion of the 119 
surgeon (video). Patients requiring single grafts or redo CABG were excluded. Patients with 120 
evolving MI (defined as the rise and fall of a biomarker together with one of a longer list of 121 
criteria comprising ischaemic symptoms, the development of pathologic Q waves, ischaemic 122 
ECG changes, and a coronary artery intervention) were also excluded. However, patients 123 
with unstable angina defined as pain on any activity or rest pain were included.  124 
Follow-up  125 
Questionnaires were sent to study participants by post every year after surgery. No clinic 126 
visits were planned apart from the routine clinical 6-week post-operative visit. Participants 127 
were sent stamped addressed envelopes to improve the return rates of postal questionnaires. 128 
Study co-ordinators contacted participants by telephone to alert them to the questionnaire’s 129 
arrival and to ask them about medications, adverse events and health services resource use. 130 
Five-year follow-up was completed for all patients included in the present analysis.   131 
Study outcomes 132 
Hospital outcomes investigated were re-exploration for bleeding, intra-aortic balloon pump 133 
(IABP) insertion, myocardial infarction (MI), cerebrovascular accident (CVA), postoperative 134 
atrial fibrillation (POAF), sternal complications revascularization and hospital mortality.  135 
Late outcomes were 5-year all-cause mortality and cumulative incidence of major cardiac and 136 
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cerebrovascular events (MACCE) including cardiovascular (CV) death, CVA, MI and repeat 137 
revascularization.  138 
Outcomes definitions 139 
Death was classified into cardiovascular and non-cardiovascular, where possible, using 140 
autopsy reports and death certificates. Congestive heart failure, arrhythmia or myocardial 141 
infarction, pulmonary embolus and dissection were considered cardiovascular causes of 142 
death.  143 
MI was diagnosed when two of the following three criteria were present: 1. Unequivocal 144 
ECG changes; 2. Elevation of cardiac enzyme(s) above twice the upper limit of normal or 145 
diagnostic troponin rises; 3. Chest pain typical for acute MI which lasted more than 20 146 
minutes.  CVA was defined as new neurological deficit evidenced by clinical signs of paresis, 147 
plegia or new cognitive dysfunction including any mental status alteration lasting more than 148 
24 hours and/or evidence on CT or MRI scan of recent brain infarct (less than 6 months). 149 
Repeat revascularization was defined as coronary bypass surgery or percutaneous coronary 150 
intervention (PCI) performed after trial procedure. Sternal complications included sternal 151 
wound infection requiring antibiotics, VAC therapy, debridement or reconstruction.  152 
Statistical analysis  153 
Multiple imputation (m=3) was used to address missing data. Rubin’s method [8] was used to 154 
combine results from each of the imputed data sets (Amelia R package). Due to lack of 155 
randomization with regards to BITA conversion, a propensity score (PS) was generated for 156 
each patient from a multivariable logistic regression model (C-statistics 0.64) based on pre-157 
specified set of covariates (as listed in Table 1) with requiring conversion vs non-converted 158 
as a binary dependent variable [9]. Pairs of patients were derived using greedy 1:3 matching 159 
with a calliper of width of 0.2 standard deviation of the logit of the PS (nonrandom R 160 
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package). The quality of the match was assessed by comparing selected pre-treatment 161 
variables in propensity score–matched patients using the standardized mean difference 162 
(SMD), with an absolute standardized difference of greater than 10% taken to represent 163 
meaningful covariate imbalance. [9]. McNemar's test and paired t-test was used to assess the 164 
statistical significance of the risk difference for hospital outcomes and stratified log-rank was 165 
used to assess the statistical significance of the risk difference for mortality and MACCE at 5 166 
years. Risk competing framework was used to estimate the treatment effect on MACCE 167 
individual components (survival R package and riskRegression R package). All p-168 
values <0.05 were considered to indicate statistical significance.  169 
Results 170 
Study population  171 
A total of 1525 patients were operated with intention to receive BITA grafting. Of those, 233 172 
(15.3%) were converted to other conduit selection strategies. Incidence of conversion largely 173 
varied across 131 participating surgeons (Figure 1 and Supplementary Table 1). The most 174 
common reason for BITA grafts conversion was the evidence of at least one internal thoracic 175 
artery (ITA) not suitable which was reported in 77 (33.0%) cases. This was due to during 176 
harvesting (n=41), poor flow without apparent injury (n=23) and conduit too short for 177 
grafting (n=13).  The second most common reasons for BITA conversion were poor target 178 
not suitable for BITA grafts in 44 cases (18.9%) and perceived increased risk for sternum 179 
complication (i.e. osteoporosis) in 38 cases (16.3%). Other causes were hemodynamic 180 
instability which occurred during BITA harvesting in 19 cases (8.1%), intraoperative 181 
evidence of other cardiac pathologies requiring intervention in 6 (2.6%) cases and time 182 
constrain in 6 (2.6%) cases. In 43 cases (18.5%), surgeons decided to not perform BITA 183 
grafts without providing a justification (Central Picture).      184 
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Baseline characteristics in the two groups are reported in Table 1. Overall subjects with 185 
intraoperative BITA graft conversion presented a higher risk profile. In particular they were 186 
more likely to be older and female and were more likely to have diabetes, chronic obstructive 187 
pulmonary disease (COPD) and left ventricular ejection fraction (LVEF)<0.5. Intraoperative 188 
data breakdown according to causes of BITA conversion showed that increased body mass 189 
index (BMI) and diabetes was more common among those converted as perceived at higher 190 
risk for risk infection, female gender was more common among those with poor targets and 191 
reduced LVEF was more common among those with those with hemodynamic instability 192 
during ITA harvesting (Supplementary Table 3). After matching the two groups were 193 
comparable for all baseline risk factors (all SMD<0.10; Figure 2).  194 
Intra-operative data 195 
Intraoperative data are summarized in Table 2. Patients who had BITA graft conversion were 196 
more likely to be undergo on-pump surgery (23.2% vs. 42.1%) and to receive a lower number 197 
of grafts (2.95±0.84 vs 3.21±0.74), with LAD (95.3% vs 99.1%) and circumflex (82% vs 198 
95.9%) territories being more likely to remain ungrafted. In the BITA conversion group, 19 199 
(8.2%) patients received SVG only. Intraoperative data breakdown according to causes of 200 
BITA conversion showed that the number of grafts was lower among those found to have 201 
poor targets (2.52±0.90), and the rate of patients receiving SVG only was higher among those 202 
with unsuitable ITA (18.2%) or hemodynamic instability during harvesting (15.8%) 203 
(Supplementary Table 4).  204 
Outcomes 205 
Hospital outcomes are summarised in Table 3. Overall patients requiring BITA graft 206 
conversion was not associated with a higher incidence of hospital morbidity or mortality. In 207 
particular, no patient requiring BITA graft conversion experienced hospital death and the 208 
need for intra-aortic balloon pump and need for repeat revascularization was comparable 209 
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between the two groups. Hospital breakdown according to causes of BITA conversion 210 
showed that those requiring conversion for hemodynamic instability during ITA harvesting 211 
presented the highest rate of IABP insertion, renal replacement therapy and postoperative MI 212 
(Supplementary Table 5).  213 
Five-year outcomes are summarised in Table 4 and Figure 3. In patients requiring conversion 214 
we found a non-significant excess of deaths (11.9% vs 8.4%; P=0.1) and MACCE (17.1% 215 
13.2%; P=0.1) mainly driven by an excess of revascularization (Figure 4). Those who 216 
required conversion for hemodynamic instability during ITA harvesting and found to have 217 
poor target or unsuitable ITA tended to have a higher rate of mortality and MACCE. 218 
(Supplementary Table 5).  219 
Conduit selection in patients initially allocated to SITA 220 
For descriptive purpose, we also reported conduits selection in those initially allocated to 221 
SITA graft. Among 1554 patients initially allocated to SITA, eight were not operated on (1 222 
death, 4 withdrew, 3 cases with no reason reported) and the remaining 1546 underwent 223 
surgery. Of those, 1494 received SITA graft (96.7%) and 38 received BITA grafts (2.5%) for 224 
the following reasons: no other suitable conduit available (n=21, 1.4%), withdrew (n=2, 225 
0.1%) and reason not report (n=15, 1.0%). Only 14 patients received neither SITA nor BITA 226 
(0.9%) for the following reasons: ITA unsuitable (n=10, 0.6%), unsuitable target (n=2, 0.1%), 227 
hemodynamic instability (n=1, 0.5%), need for unplanned surgery (n=1, 0.5%).   228 
Discussion 229 
Reasons beyond underutilization of the BITA graft remains uncertain [4,5]. Many surgeons 230 
just do not perform BITA grafts in view of the increased risk of sternal wound [10] and 231 
technical complexity [4]. However, the incidence of intraoperative BITA grafts conversion to 232 
other graft strategies in patients initially intended to receive BITA grafts remains unknown 233 
[7]. The perceived increased risk of operative morbidity related to intraoperative conversion 234 
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can partially contribute to the reluctance of many surgeons to perform BITA grafts also in 235 
view of the current intense professional and public scrutiny of cardiac surgeons’.  236 
The ART trial represents a unique opportunity to investigate the incidence and causes of 237 
intraoperative BITA graft conversion [7]. Interestingly, despite participating surgeons were 238 
anticipated to be expert in BITA grafts, the rate of intraoperative conversion was not 239 
irrelevant. In fact 15.3% of patients initially intended to received BITA grafts required 240 
intraoperative conversion to other conduit strategies. However, we noticed that there was a 241 
very large variation in BITA grafting conversion across centres and surgeons which supports 242 
the central role for individual surgeon experience. Interestingly, unsuitable ITA was reported 243 
as the main reason (33%) for intraoperative BITA grafts conversion to other conduit 244 
strategies and it was mainly related to injury during harvesting. Of notice, the rate of 245 
unsuitable ITA in those allocated to SITA graft was only 0.6% suggesting that harvesting two 246 
ITAs is more demanding and can influence surgeon’s precisions. In addition, in 44 patients, 247 
BITA was not performed because of poor target. Among those patients, only 7 patients 248 
requited 1 grafts only. In all other cases, SVG and/or RA were used in addition to SITA 249 
grafts, suggesting that technical difficulty of performing BITA grafts rather than the absence 250 
of graftable targets. We also found that 19 patients become unstable during BITA harvesting 251 
and we can hypothesis that prolonged heart compression secondary to the use of chest 252 
retractor during ITA harvesting may not be always tolerated especially in presence of reduced 253 
LVEF. On the other hand, a main reason for conversion not related to complication or 254 
technical complexity was the perception of increased risk of sternal wound complication after 255 
chest opening (i.e. osteoporotic sternum). In case of intraoperative conversion, SITA plus 256 
SVG was the most commonly opted strategy followed by SITA plus RA. Of note, 19 patients 257 
(8.2%) received SVG only.  258 
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In contrast to other clinical scenarios when intraoperative conversion significantly increases 259 
operative morbidity and mortality such as off-pump to on-pump conversion [11], BITA grafts 260 
conversion was not associated with significantly higher rate of operative complications 261 
although those requiring conversion for hemodynamic instability during ITA harvesting 262 
presented a numerically higher rate of IABP insertion, renal replacement therapy and 263 
postoperative MI. At 5 years, we found a non-significant trend towards an excess of death 264 
and MACCE in patients requiring intraoperative conversion in particular among those with 265 
perioperative hemodynamic instability, poor target and unsuitable ITA. We can speculate that 266 
perioperative myocardial injury, lower number of grafts and excess of SVG only strategy in 267 
these three groups respectively might have partially contributed to this trend. 268 
The unique technical challenges of BITA grafts fuels the perception that adoption of this 269 
myocardial revascularization strategy may increase operative morbidity in particular when 270 
intraoperative conversion to other conduit strategies is required. The present results support 271 
the hypothesis that BITA conversion does not significantly increase operative morbidity. 272 
However, the large variation in BITA conversion and its potential implication on late 273 
outcomes highlight the importance of negotiating the learning curve with appropriate patient 274 
selection, individualized grafting strategy, peer-to-peer training of the entire team, and graded 275 
clinical experience.  276 
There are two main limitations in the present analysis. This is a retrospective analysis of the 277 
ART and we cannot exclude residual confounding factors between the two groups despite 278 
propensity score adjustment. The number of patients requiring conversion was relatively 279 
small and there was a relatively low incidence of adverse events. Therefore, the analysis was 280 
likely to be underpowered to detect significant difference between groups for comparisons. 281 
Finally, we had no information whether BITA injury during harvesting occurred with 282 
skeletonised or pedicled technique.  283 
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In conclusion, the incidence of intraoperative BITA graft conversion is not irrelevant also 284 
among experienced surgeons participating in ART. While intraoperative BITA grafts 285 
conversion does not increase the risk of operative mortality and major complications, BITA 286 
conversion might be associated with poorer outcomes at long term follow-up. However, the 287 
latter conclusions require further investigations.    288 
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Table 1. Baseline characteristics 362 
  Requiring 
Conversion 
Not  
Converted 
Before PSM 
SMD 
before 
PSM 
Not converted 
matched 
SMD 
after PSM 
N 233 1292  699  
Age (mean (sd)) 65 (9) 63 (9) 0.229 65 (8) 0.019 
Female = 1 (\%) 47 (20.2) 176 (13.6) 0.175 135 (19.3) 0.022 
BMI (mean (sd)) 29 (4) 28 (4) 0.117 29 (4) 0.005 
SBP (mean (sd)) 132 (18) 132 (18) 0.003 132 (18) 0.015 
DBP (mean (sd)) 75 (11) 75 (11) 0.011 75 (11) 0.016 
Creatinine (mmol/L)  95 (21) 97 (21.5) 0.061 96 (21) 0.015 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
SMD: standardized mean difference; PSM: propensity score matching; BMI: body mass 363 
index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic 364 
obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic 365 
attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous 366 
coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: 367 
left main disease.  368 
  369 
NYHA III/IV n(%) 42 (18.0) 290 (22.4) 0.110 131 (18.7) 0.018 
Unstable angina n(%) 14 (6.0) 102 (7.9) 0.074 43 (6.2) 0.006 
Treated Hypertension  177 (76.0) 1002 (77.6) 0.038 543 (77.7) 0.041 
Treated Hyperlipaemia  222 (95.3) 1216 (94.1) 0.052 663 (94.8) 0.020 
Diabetes n(%)   0.140  0.046 
No 165 (70.8) 994 (76.9)  508 (72.7)  
On insulin 17 ( 7.3) 76 ( 5.9)  51 ( 7.3)  
Oral 51 (21.9) 222 (17.2)  140 (20.0)  
Smoking n(%)   0.046  0.032 
Current 32 (13.7) 198 (15.3)  92 (13.2)  
Ex 129 (55.4) 696 (53.9)  381 (54.5)  
Never 72 (30.9) 398 (30.8)  226 (32.3)  
COPD n(%) 13 (5.6) 29 (2.2) 0.173 26 (3.7) 0.088 
Asthma n(%) 11 (4.7) 67 (5.2) 0.021 32 (4.6) 0.007 
PVD n(%) 17 (7.3) 85 (6.6) 0.028 49 (7.0) 0.011 
TIA n(%) 8 (3.4) 42 (3.3) 0.010 19 (2.7) 0.041 
CVA n(%) 5 (2.1) 37 (2.9) 0.046 12 (1.7) 0.031 
MI n(%) 104 (44.6) 506 (39.2) 0.111 322 (46.1) 0.029 
PCI n(%) 40 (17.2) 198 (15.3) 0.050 117 (16.7) 0.011 
Preop AF pre n(%) 4 (1.7) 15 (1.2) 0.047 11 (1.6) 0.011 
LVEF\_pre (\%)   0.187  0.033 
≤?50% (good) 161 (69.1) 994 (76.9)  473 (67.7)  
31-49% (moderate) 67 (28.8) 268 (20.7)  209 (29.9)  
≤?30% (poor) 5 (2.1) 30 (2.3)  17 (2.4)  
LMD  n(%) 40 (17.2) 282 (21.8) 0.118 127 (18.2) 0.026 
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Table 2. Intraoperative data 370 
 Requiring 
Conversion 
Not  
Converted 
Before PSM 
P-value 
Before 
PSM 
Not converted 
matched 
P-value 
After PSM 
n 233 1292  699  
Off-pump  n(%) 54 (23.2) 584 (45.2) <0.001 294 (42.1) <0.001 
LAD  n(%) 222 (95.3) 1278 (98.9) <0.001 693 (99.1) <0.001 
Circumflex  n(%) 191 (82.0) 1231 (95.3) <0.001 670 (95.9) <0.001 
RCA  n(%) 157 (67.4) 890 (68.9) 0.705 488 (69.8) 0.539 
Diagonal branches  n(%) 64 (27.5) 395 (30.6) 0.382 206 (29.5) 0.617 
N grafts (mean (sd)) 2.95 (0.84) 3.21 (0.77) <0.001 3.21 (0.74) <0.001 
Conduits (%)   <0.001  <0.001 
     Unknown  0 ( 0.0) 2 ( 0.2)  0 ( 0.0)  
     BITA  270 (20.9)  139 (19.9)  
     BITA+RA  215 (16.6)  115 (16.5)  
     BITA+RA+SV  44 ( 3.4)  23 ( 3.3)  
     BITA+SV  761 (58.9)  422 (60.4)  
     LITA 7 ( 3.0)     
     LITA+RA 22 ( 9.4)     
     LITA+RA+SV 12 ( 5.2)     
     LITA+SV 156 (67.0)     
     RA 1 ( 0.4)     
     RA+SV 2 ( 0.9)     
     RITA 3 ( 1.3)     
     RITA+RA 2 ( 0.9)     
     RITA+RA+SV 1 ( 0.4)     
     RITA+SV 8 ( 3.4)     
     SVG 19 ( 8.2)     
PSM: propensity score matching; LAD: left anterior descending artery; RCA: right coronary 371 
artery; BITA; bilateral internal thoracic arteries; RA: radial artery; SVG: saphenous vein graft  372 
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Table 3. Hospital outcomes 373 
  Requiring 
Conversion 
Not  
Converted 
Before 
PSM 
P-value 
Before 
PSM 
Not  
converted 
matched 
P-value 
After 
PSM 
N 233 1292  699  
Re-exploration for bleeding n(%) 10 (4.3) 47 (3.6) 0.8 20 (2.9) 0.4 
IABP insertion n(%) 12 (5.2) 55 (4.3) 0.7 36 (5.2) 1 
Renal replacement therapy n(%) 6 (2.6) 85 (6.6) 0.03 52 (7.4) 0.01 
Sternal complications n(%) 13 (5.6) 64 (5.0) 0.8 36 (5.2) 0.9 
Death n(%) 0 (0.0) 17 (1.3) 0.2 11 (1.6) 0.1 
MI n(%) 7 (3.0) 18 (1.4) 0.1 12 (1.7) 0.4 
CVA n(%) 5 (2.1) 13 (1.0) 0.2 9 (1.3) 0.5 
Revascularization n(%) 1 (0.4) 9 (0.7) 1 5 (0.7) 1 
POAF n(%) 69 (29.6) 329 (25.5) 0.2 208 (29.8) 1 
PSM: propensity score matching; IABP: intra-aortic balloon pump; Myocardial infarction; 374 
CVA: cerebrovascular accident; POAF: postoperative atrial fibrillation  375 
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Table 4. Five-year outcomes   376 
  Converted Not  
Converted 
Before PSM 
P-value 
Before 
PSM 
Not converted 
matched 
P-value 
N 233 1292  699  
Mortality at 5 years 27(11.9) 104(8.2) 0.08 58(8.4) 0.1 
MACCE at 5 years 39(17.1) 155(12.4) 0.03 90(13.2) 0.1 
cardiovascular death 8(3.5) 44(3.5) 1 29(4.2) 0.7 
MI 9(3.9) 42(3.3) 0.6 24(3.5) 0.7 
CVA 7(3.0) 31(2.4) 0.6 19(2.7) 0.8 
Revascularization 12(8.2) 81(6.4) 0.2 43(6.2) 0.2 
PSM: propensity score matching; MACCE: major adverse cardiac and cerebrovascular 377 
events; MI: myocardial infarction; CVA: cerebrovascular accident 378 
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Figure Legend 380 
Central Picture: BITA grafts allocation and conversion in the ART (BITA: bilateral interval 381 
thoracic artery; SITA: single internal thoracic artery; ITA: internal thoracic artery) 382 
Figure 1. Scatter plot showing total number of cases initially allocated to BITA grafts 383 
performed by individual surgeons and relative rate of BITA conversion. 384 
Figure 2. Changes in standardized mean after matching (SMD: standardized mean difference; 385 
PSM: propensity score matching; BMI: body mass index; SBP: systolic blood pressure; DBP: 386 
diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral 387 
vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: 388 
myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; 389 
LVEF: left ventricular ejection fraction; LMD: left main disease).  390 
Figure 3. Cumulative incidence of mortality and major adverse cardiac and cerebrovascular 391 
events (MACCE) in the matched sample 392 
Figure 4. Cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI), 393 
cerebrovascular accident (CVA) and revascularization in the matched sample 394 
Video. Skeletonised left internal thoracic artery during off-pump surgery   395 
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Supplementary Table 1. Number of cases performed initially allocated to bilateral interval 396 
thoracic artery (BITA) grafts and BITA conversion rate. 397 
#Surgeon 
Total number of 
cases performed 
initially allocated to 
BITA grafts 
%BITA grafts conversion 
Unknow 67 23.9% 
1 1 0.0% 
2 1 100.0% 
3 1 0.0% 
4 1 0.0% 
5 1 100.0% 
6 15 0.0% 
7 9 22.2% 
8 6 0.0% 
9 1 100.0% 
10 9 33.3% 
11 1 0.0% 
12 1 100.0% 
13 2 100.0% 
14 1 0.0% 
15 1 0.0% 
16 15 6.7% 
17 5 0.0% 
18 8 0.0% 
19 18 5.6% 
20 17 5.9% 
21 15 13.3% 
22 6 33.3% 
23 20 20.0% 
24 9 11.1% 
25 15 0.0% 
26 7 28.6% 
27 30 30.0% 
28 5 0.0% 
29 6 0.0% 
30 8 50.0% 
31 4 0.0% 
32 9 0.0% 
33 15 13.3% 
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34 7 0.0% 
35 40 10.0% 
36 1 0.0% 
37 4 25.0% 
38 10 50.0% 
39 13 23.1% 
40 7 28.6% 
41 1 0.0% 
42 2 0.0% 
43 12 16.7% 
44 1 0.0% 
45 12 41.7% 
46 2 0.0% 
47 2 0.0% 
48 1 0.0% 
49 34 20.6% 
50 9 55.6% 
51 24 8.3% 
52 15 26.7% 
53 17 70.6% 
54 1 0.0% 
55 5 0.0% 
56 1 0.0% 
57 29 20.7% 
58 8 25.0% 
59 1 0.0% 
60 4 25.0% 
61 7 42.9% 
62 3 0.0% 
63 1 0.0% 
64 5 0.0% 
65 8 37.5% 
66 12 16.7% 
67 2 50.0% 
68 17 23.5% 
69 28 3.6% 
70 14 21.4% 
71 1 100.0% 
72 4 0.0% 
73 2 0.0% 
74 29 10.3% 
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75 41 0.0% 
76 18 38.9% 
77 22 31.8% 
78 4 25.0% 
79 3 100.0% 
80 1 0.0% 
81 33 6.1% 
82 4 0.0% 
83 1 0.0% 
84 9 0.0% 
85 1 0.0% 
86 16 0.0% 
87 1 0.0% 
88 1 0.0% 
89 2 50.0% 
90 16 6.3% 
91 11 54.5% 
92 19 21.1% 
93 3 33.3% 
94 19 42.1% 
95 1 100.0% 
96 4 0.0% 
97 1 100.0% 
98 1 0.0% 
99 18 5.6% 
100 22 13.6% 
101 2 0.0% 
102 2 0.0% 
103 8 0.0% 
104 33 0.0% 
105 1 0.0% 
106 12 16.7% 
107 12 8.3% 
108 3 0.0% 
109 4 100.0% 
110 1 0.0% 
111 2 100.0% 
112 22 18.2% 
113 4 0.0% 
114 10 10.0% 
115 2 0.0% 
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116 2 0.0% 
117 1 0.0% 
118 211 1.9% 
119 1 0.0% 
120 16 25.0% 
121 1 0.0% 
122 15 33.3% 
123 8 0.0% 
124 3 0.0% 
125 1 100.0% 
126 11 9.1% 
127 3 0.0% 
128 1 0.0% 
129 33 15.2% 
130 99 13.1% 
131 3 33.3% 
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Supplementary Table 2. Baseline characteristics according to cause of bilateral interval thoracic artery (BITA) grafts conversion   
 High risk for 
sternal 
complication 
At least 1  
ITA not  
suitable 
Target  
not suitable 
Other  
cardiac 
pathologies 
Justification  
not provided 
Time 
constrain 
Unstable 
during ITA 
harvesting 
N 38 77 44 6 43 6 19 
Age (mean (sd)) 65.01 (8.87) 65.59 (8.19) 65.64 (9.39) 68.88 (8.63) 64.43 (8.63) 64.44 (8.29) 65.76 (8.68) 
Female n(%) 7 (18.4) 16 (20.8) 12 (27.3) 0 (0.0) 10 (23.3) 0 (0.0) 2 (10.5) 
BMI (mean (sd)) 30.21 (4.28) 27.51 (3.25) 28.82 (3.11) 27.91 (2.60) 29.53 (4.01) 29.10 (2.85) 28.54 (4.61) 
SBP (mean (sd)) 132 (15) 131 (20) 134 (19) 129 (15) 130 (16) 140 (12) 131 (17) 
DBP (mean (sd)) 78 (10) 74 (10) 75 (10) 81 (11) 74 (13) 80 (15) 74 (10) 
Creatinine (mmol/L)  97.49 (23.50) 94.27 (18.31) 99.48 (25.05) 100.08 (25.67) 92.51 (18.37) 89.00 (11.47) 93.85 (20.55) 
NYHA III/IV n(%) 4 (10.5) 17 (22.1) 6 (13.6) 2 (33.3) 8 (18.6) 2 (33.3) 3 (15.8) 
Unstable angina n(%) 1 (2.6) 6 (7.8) 3 (6.8) 1 (16.7) 1 (2.3) 0 (0.0) 2 (10.5) 
Treated Hypertension  29 (76.3) 53 (68.8) 33 (75.0) 6 (100.0) 32 (74.4) 6 (100.0) 18 (94.7) 
Treated Hyperlipaemia  38 (100.0) 73 (94.8) 42 (95.5) 6 (100.0) 39 (90.7) 6 (100.0) 18 (94.7) 
Diabetes n(%)        
No 24 (63.2) 56 (72.7) 30 (68.2) 4 (66.7) 29 (67.4) 4 (66.7) 18 (94.7) 
On insulin 3 (7.9) 9 (11.7) 2 (4.5) 0 (0.0) 3 (7.0) 0 (0.0) 0 (0.0) 
Oral 11 (28.9) 12 (15.6) 12 (27.3) 2 (33.3) 11 (25.6) 2 (33.3) 1 (5.3) 
Smoking n(%)        
Current 6 (15.8) 7 (9.1) 7 (15.9) 1 (16.7) 7 (16.3) 1 (16.7) 3 (15.8) 
Ex 18 (47.4) 46 (59.7) 24 (54.5) 2 (33.3) 22 (51.2) 4 (66.7) 13 (68.4) 
Never 14 (36.8) 24 (31.2) 13 (29.5) 3 (50.0) 14 (32.6) 1 (16.7) 3 (15.8) 
COPD n(%) 3 (7.9) 4 (5.2) 1 (2.3) 0 (0.0) 4 (9.3) 0 (0.0) 1 (5.3) 
Asthma n(%) 3 (7.9) 1 (1.3) 0 (0.0) 1 (16.7) 6 (14.0) 0 (0.0) 0 (0.0) 
PVD n(%) 4 (10.5) 5 (6.5) 1 (2.3) 1 (16.7) 4 (9.3) 0 (0.0) 2 (10.5) 
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TIA n(%) 2 (5.3) 3 (3.9) 3 (6.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
CVA n(%) 1 (2.6) 1 (1.3) 1 (2.3) 1 (16.7) 0 (0.0) 0 (0.0) 1 (5.3) 
MI n(%) 13 (34.2) 38 (49.4) 21 (47.7) 2 (33.3) 21 (48.8) 2 (33.3) 7 (36.8) 
PCI n(%) 14 (36.8) 10 (13.0) 9 (20.5) 1 (16.7) 2 (4.7) 0 (0.0) 4 (21.1) 
Preop AF pre n(%) 2 (5.3) 1 (1.3) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 0 (0.0) 
LVEF\_pre (\%)        
≤?50% (good) 31 (81.6) 52 (67.5) 30 (68.2) 3 (50.0) 31 (72.1) 4 (66.7) 10 (52.6) 
31-49% (moderate) 6 (15.8) 24 (31.2) 12 (27.3) 3 (50.0) 12 (27.9) 2 (33.3) 8 (42.1) 
≤?30% (poor) 1 (2.6) 1 (1.3) 2 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.3) 
LMD  n(%) 7 (18.4) 14 (18.2) 7 (15.9) 1 (16.7) 5 (11.6) 3 (50.0) 3 (15.8) 
ITA: internal thoracic artery; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive 
pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial 
infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease.  
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Supplementary Table 3. Operative data according to cause of bilateral interval thoracic artery (BITA) grafts conversion.  
  
High risk for 
sternal 
complication 
At least 1  
ITA not  
suitable 
Target  
not suitable 
Other  
cardiac 
pathologies 
Justification  
not provided 
Time 
constrain 
Unstable 
during ITA 
harvesting 
n 38 77 44 6 43 6 19 
Off-pump  n(%) 4 (10.5) 23 (29.9) 15 (34.1) 1 (16.7) 9 (20.9) 0 (0.0) 2 (10.5) 
LAD  n(%) 37 (97.4) 76 (98.7) 37 (84.1) 5 (83.3) 43 (100.0) 6 (100.0) 18 (94.7) 
Circumflex  n(%) 37 (97.4) 70 (90.9) 25 (56.8) 5 (83.3) 33 (76.7) 6 (100.0) 15 (78.9) 
RCA  n(%) 24 (63.2) 52 (67.5) 31 (70.5) 3 (50.0) 26 (60.5) 6 (100.0) 15 (78.9) 
Diagonal branches  n(%) 12 (31.6) 22 (28.6) 7 (15.9) 1 (16.7) 14 (32.6) 2 (33.3) 6 (31.6) 
N grafts (mean (sd)) 3.03 (0.79) 3.04 (0.77) 2.52 (0.90) 2.83 (1.47) 3.00 (0.82) 3.50 (0.55) 3.16 (0.76) 
Conduits (%) 
       
     LITA 0 ( 0.0) 0 ( 0.0) 4 ( 9.1) 1 (16.7) 2 (  4.7) 0 (  0.0) 0 ( 0.0) 
     LITA+RA 2 ( 5.3) 3 ( 3.9) 4 ( 9.1) 0 ( 0.0) 13 ( 30.2) 0 (  0.0) 0 ( 0.0) 
     LITA+RA+SV 5 (13.2) 1 ( 1.3) 1 ( 2.3) 0 ( 0.0) 4 (  9.3) 0 (  0.0) 1 ( 5.3) 
     LITA+SV 30 (78.9) 48 (62.3) 32 (72.7) 5 (83.3) 21 ( 48.8) 5 ( 83.3) 15 (78.9) 
     RA 0 ( 0.0) 0 ( 0.0) 1 ( 2.3) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RA+SV 0 ( 0.0) 2 ( 2.6) 0 ( 0.0) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA 0 ( 0.0) 1 ( 1.3) 2 ( 4.5) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA+RA 0 ( 0.0) 1 ( 1.3) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 0 (  0.0) 0 ( 0.0) 
     RITA+RA+SV 0 ( 0.0) 1 ( 1.3) 0 ( 0.0) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA+SV 0 ( 0.0) 6 ( 7.8) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 1 ( 16.7) 0 ( 0.0) 
     SVG 1 ( 2.6) 14 (18.2) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 0 (  0.0) 3 (15.8) 
ITA: internal thoracic artery; LAD: left anterior descending artery; RCA: right coronary artery; BITA; bilateral internal thoracic arteries; RA: 
radial artery; SVG: saphenous vein graft 
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Supplementary Table 4. Hospital outcomes and 5-year mortality and major adverse cardiac and cerebrovascular events (MACCE) according to 
cause of bilateral interval thoracic artery (BITA) grafts conversion   
  
High risk for 
sternal 
complication 
ITA not suitable Target not 
suitable 
Other cardiac 
pathologies 
Justification 
not provided 
Time 
constrain 
Unstable 
during 
harvesting 
N 38 77 44 6 43 6 19 
Re-exploration for bleeding n(%) 0 (0.0) 2 (2.6) 2 (4.5) 0 (0.0) 6 (14.0) 0 (0.0) 0 ( 0.0) 
IABP insertion n(%) 3 (7.9) 3 (3.9) 1 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 5 (26.3) 
Renal replacement therapy n(%) 1 (2.6) 1 (1.3) 1 (2.3) 0 (0.0) 1 (2.3) 1 (16.7) 1 ( 5.3) 
Sternal complications  n(%) 3 (7.9) 2 (2.6) 2 (4.5) 1 (16.7) 4 (9.3) 0 (0.0) 1 ( 5.3) 
Death  n(%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 ( 0.0) 
MI  n(%) 0 (0.0) 4 (5.2) 1 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (10.5) 
CVA  n(%) 1 (2.6) 3 (3.9) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 ( 0.0) 
Revascularization n(%) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 ( 0.0) 
POAF  n(%) 12 (31.6) 21 (27.3) 13 (29.5) 4 (66.7) 10 (23.3) 2 (33.3) 7 (36.8) 
Mortality at 5 years 4 (10.5) 9(11.9) 6(13.8) 0(0) 6(14.1) 0(0) 2(10.8) 
MACCE at 5 years 3(8) 18(24) 8(18.3) 1(16.7) 4(9.7) 1(16.7) 4(21.1) 
ITA: internal thoracic artery; IABP: intra-aortic balloon pump; Myocardial infarction; CVA: cerebrovascular accident; POAF: postoperative 
atrial fibrillation; MACCE: major adverse cardiac and cerebrovascular events 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
